Cayman Zm 306416; Purity- Greater Than Or Equal To 98%; Size- 5 M

Meclofenoxate is a nootropic agent. It inhibits norepinephrine reuptake by isolated rat striatal synaptosomes (IC₅₀ = 0.5 mM) and serotonin (5-HT) reuptake by isolated rat cortical synaptosomes (IC₅₀ = 2.7 mM). Meclofenoxate increases survival of dopaminergic neurons in a C. elegans psd-1 knockdown model of Parkinsons disease. It reduces rotenone-induced depletion of dopamine and glutathione (GSH), lipid peroxidation, production of nitric oxide (NO), and cortical and cerebral damage, as well as enhances activity of catalase and superoxide dismutase in a rat model of Parkinsons disease when administered at a dose of 100 mg/kg. Meclofenoxate (100 mg/kg) increases synaptic surface density and reduces age-induced decreases in synaptic numerical density in aged rats. It also reduces neuronal lipofuscin pigment, a marker of aging, in the cerebral cortex and hippocampus and improves learning and memory in the T-maze in aged mice. Formulations containing meclofenoxate have been used in the treatment of senile dementia.

WARNING This product is not for human or veterinary use.